GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Cash From Discontinued Investing Activities

Sino Biopharmaceutical (FRA:SMZ1) Cash From Discontinued Investing Activities : €0 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sino Biopharmaceutical's cash from discontinued investing activities for the six months ended in Jun. 2024 was €0 Mil. It means Sino Biopharmaceutical received €0 Mil from discontinued investing activities. Sino Biopharmaceutical's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Jun. 2024 was €0 Mil.


Sino Biopharmaceutical Cash From Discontinued Investing Activities Historical Data

The historical data trend for Sino Biopharmaceutical's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Cash From Discontinued Investing Activities Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sino Biopharmaceutical Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Industry
Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines